Atopic dermatitis (AD) is a common inflammatory skin disease with high prevalence both in children (15-30%) and adults (2-10%); limited data are available for the elderly. Elderly patients are challenging showing frequent multiple comorbidities, associated polypharmacy, and common previously treatments failure. We performed a retrospective observational study on elderly (≥ 65 year-old) patients treated with dupilumab, monoclonal antibody to the shared alpha subunit of the IL4 and IL-13 receptor approved for the treatment of moderate-to-severe AD in adults.
Efficacy and safety of dupilumab in atopic dermatitis of the elderly: A retrospective study
Patruno, C
2020-01-01
Abstract
Atopic dermatitis (AD) is a common inflammatory skin disease with high prevalence both in children (15-30%) and adults (2-10%); limited data are available for the elderly. Elderly patients are challenging showing frequent multiple comorbidities, associated polypharmacy, and common previously treatments failure. We performed a retrospective observational study on elderly (≥ 65 year-old) patients treated with dupilumab, monoclonal antibody to the shared alpha subunit of the IL4 and IL-13 receptor approved for the treatment of moderate-to-severe AD in adults.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
